News Chiesi starts rare diseases division, ahead of potential Fab... Italian pharma Chiesi has begun a new rare diseases division as it builds towards a potential commercial launch for its Fabry Disease therapy.
News FDA rejection scuppers AZ’s hopes of a COPD triple clash wit... The FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by
Market Access Verona to take COPD hopeful into phase 3 Verona Pharma is to take lung drug RPL554 into late clinical development after a successful phase 2b trial.
News Europe: thumbs up for Roche's Hemlibra, Chiesi rare disease ... Drug has been approved in US since November
News EU regulators back Chiesi drug for rare inherited disease Decision paves way for licence to treat alpha-mannosidosis,
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends